Decoy Therapeutics Inc.
DCOY
$2.99
$0.010.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 1,020.53% | -- | -- | -- | -- |
| Gross Profit | -825.00% | -- | -- | -- | -- |
| SG&A Expenses | 56.23% | -6.65% | -77.82% | -4.13% | -32.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 172.47% | 32.87% | -74.02% | -11.07% | -34.20% |
| Operating Income | -148.90% | -32.87% | 74.02% | 11.07% | 34.20% |
| Income Before Tax | -147.84% | -30.13% | -513.27% | 10.14% | 32.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -147.84% | -30.13% | -513.27% | 10.14% | 32.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -147.84% | -30.13% | -513.27% | 10.14% | 32.76% |
| EBIT | -148.90% | -32.87% | 74.02% | 11.07% | 34.20% |
| EBITDA | -147.78% | -32.62% | 74.20% | 11.08% | 34.23% |
| EPS Basic | 94.51% | 8.70% | -412.14% | -- | -- |
| Normalized Basic EPS | 94.51% | -- | 80.45% | -- | -- |
| EPS Diluted | 94.51% | 8.70% | -412.14% | -- | -- |
| Normalized Diluted EPS | 94.51% | -- | 80.45% | -- | -- |
| Average Basic Shares Outstanding | 4,408.47% | -- | 19.74% | -- | -- |
| Average Diluted Shares Outstanding | 4,408.47% | 66.46% | 19.74% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |